DCTH logo

DCTH
Delcath Systems Inc

26,279
Mkt Cap
$342.54M
Volume
413,758.00
52W High
$18.23
52W Low
$8.12
PE Ratio
1,127.91
DCTH Fundamentals
Price
$9.70
Prev Close
$9.64
Open
$9.60
50D MA
$10.10
Beta
1.08
Avg. Volume
1.07M
EPS (Annual)
-$0.9254
P/B
2.98
Rev/Employee
$387,552.08
Loading...
Loading...
News
all
press releases
Do Options Traders Know Something About Delcath Systems Stock We Don't?
Investors need to pay close attention to Delcath Systems stock based on the movements in the options market lately.
Zacks·5d ago
News Placeholder
More News
News Placeholder
Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages
Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat.com...
MarketBeat·6d ago
News Placeholder
Delcath Systems (NASDAQ:DCTH) Board Authorizes Stock Repurchase Plan
Delcath Systems (NASDAQ:DCTH - Get Free Report) announced that its Board of Directors has approved a share repurchase program on Thursday, November 20th, RTT News reports. The company plans to...
MarketBeat·8d ago
News Placeholder
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Delcath Systems, Inc. (Nasdaq: DCTH), (Delcath) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors...
Business Wire·9d ago
News Placeholder
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
Delcath Systems, Inc. (Nasdaq: DCTH), (Delcath or the Company) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of...
Business Wire·11d ago
News Placeholder
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. (Nasdaq: DCTH) (the Company or Delcath), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company...
Business Wire·15d ago
News Placeholder
Delcath Systems (NASDAQ:DCTH) CEO Gerard Michel Acquires 11,500 Shares of Stock
Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) CEO Gerard Michel bought 11,500 shares of the firm's stock in a transaction dated Tuesday, November 11th. The shares were purchased at an average...
MarketBeat·15d ago
News Placeholder
Delcath Systems (NASDAQ:DCTH) CEO Gerard Michel Acquires 11,500 Shares
Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) CEO Gerard Michel purchased 11,500 shares of Delcath Systems stock in a transaction that occurred on Tuesday, November 11th. The shares were...
MarketBeat·15d ago
News Placeholder
Los Angeles Capital Management LLC Purchases New Holdings in Delcath Systems, Inc. $DCTH
Los Angeles Capital Management LLC purchased a new stake in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the second quarter, according to its most recent 13F filing with the Securities...
MarketBeat·15d ago
News Placeholder
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
Delcath Systems, Inc. (Nasdaq: DCTH), (Delcath or the Company) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of...
Business Wire·16d ago

Latest DCTH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.